Journal: The Ochsner Journal

Article Title: Right Heart Failure in Different Left Ventricular Assist Devices: Single-Center Experience

doi: 10.31486/toj.19.0025

Figure Lengend Snippet: Preoperative Demographics and Clinical Status

Article Snippet: In comparing survival between the types of LVAD, the survival rate of the HeartMate II group exceeded that of the HVAD group at 1 year (82.1% vs 67.2%) and 2 years (74.6% vs 61.7%), but this difference did not achieve statistical significance (log-rank P =0.087) ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure. caption a7 Kaplan-Meier survival analysis for the HeartMate II and HeartWare ventricular assist device (HVAD) groups.

Techniques: Significance Assay

Journal: The Ochsner Journal

Article Title: Right Heart Failure in Different Left Ventricular Assist Devices: Single-Center Experience

doi: 10.31486/toj.19.0025

Figure Lengend Snippet: Postoperative Outcomes

Article Snippet: In comparing survival between the types of LVAD, the survival rate of the HeartMate II group exceeded that of the HVAD group at 1 year (82.1% vs 67.2%) and 2 years (74.6% vs 61.7%), but this difference did not achieve statistical significance (log-rank P =0.087) ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure. caption a7 Kaplan-Meier survival analysis for the HeartMate II and HeartWare ventricular assist device (HVAD) groups.

Techniques:

Journal: The Ochsner Journal

Article Title: Right Heart Failure in Different Left Ventricular Assist Devices: Single-Center Experience

doi: 10.31486/toj.19.0025

Figure Lengend Snippet: Kaplan-Meier survival analysis for the HeartMate II and HeartWare ventricular assist device (HVAD) groups.

Article Snippet: In comparing survival between the types of LVAD, the survival rate of the HeartMate II group exceeded that of the HVAD group at 1 year (82.1% vs 67.2%) and 2 years (74.6% vs 61.7%), but this difference did not achieve statistical significance (log-rank P =0.087) ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure. caption a7 Kaplan-Meier survival analysis for the HeartMate II and HeartWare ventricular assist device (HVAD) groups.

Techniques:

Journal: Journal of vascular surgery

Article Title: SUPERIOR MESENTERIC ARTERY CALCIFICATION IS ASSOCIATED WITH CARDIOVASCULAR RISK FACTORS, SYSTEMIC CALCIFIED ATHEROSCLEROSIS AND INCREASED MORTALITY

doi: 10.1016/j.jvs.2017.08.081

Figure Lengend Snippet: Logistic regression model of risk factors for the presence of superior mesenteric artery calcification

Article Snippet: Similarly, the mean survival from cardiovascular mortality for those without SMAC was 10.7 years (10.71–10.75), compared to 10.2 years (9.94–10.39) for those with SMAC. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure I caption a7 caption a8 Kaplan-Meier curve for overall survival among those with or without superior mesenteric artery calcification There is a significant difference in cumulative overall survival between those with and without SMAC (log rank test P<.001).

Techniques:

Journal: Journal of vascular surgery

Article Title: SUPERIOR MESENTERIC ARTERY CALCIFICATION IS ASSOCIATED WITH CARDIOVASCULAR RISK FACTORS, SYSTEMIC CALCIFIED ATHEROSCLEROSIS AND INCREASED MORTALITY

doi: 10.1016/j.jvs.2017.08.081

Figure Lengend Snippet: Linear regression models of risk factors for the extent of superior mesenteric artery calcification

Article Snippet: Similarly, the mean survival from cardiovascular mortality for those without SMAC was 10.7 years (10.71–10.75), compared to 10.2 years (9.94–10.39) for those with SMAC. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure I caption a7 caption a8 Kaplan-Meier curve for overall survival among those with or without superior mesenteric artery calcification There is a significant difference in cumulative overall survival between those with and without SMAC (log rank test P<.001).

Techniques:

Journal: Journal of vascular surgery

Article Title: SUPERIOR MESENTERIC ARTERY CALCIFICATION IS ASSOCIATED WITH CARDIOVASCULAR RISK FACTORS, SYSTEMIC CALCIFIED ATHEROSCLEROSIS AND INCREASED MORTALITY

doi: 10.1016/j.jvs.2017.08.081

Figure Lengend Snippet: Hazard of all-cause or cardiovascular mortality given superior mesenteric artery calcification presence or extent.

Article Snippet: Similarly, the mean survival from cardiovascular mortality for those without SMAC was 10.7 years (10.71–10.75), compared to 10.2 years (9.94–10.39) for those with SMAC. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure I caption a7 caption a8 Kaplan-Meier curve for overall survival among those with or without superior mesenteric artery calcification There is a significant difference in cumulative overall survival between those with and without SMAC (log rank test P<.001).

Techniques:

Journal: Journal of Virology

Article Title: PrP C Governs Susceptibility to Prion Strains in Bank Vole, While Other Host Factors Modulate Strain Features

doi: 10.1128/JVI.01592-16

Figure Lengend Snippet: Isolates used in this study

Article Snippet: Survival curves of the Bv109M groups inoculated with BSE-derived prions were generated by the Kaplan-Meier method and verified by the log-rank (Mantel-Cox) test. table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Isolate Description Supplier a Reference Ca-BSE-1 Naturally BSE-infected cow; Italy (1994) ISS 9 Ca-BSE-2 Naturally BSE-infected cow; UK (PG1199/00) VLA 41 Ca-BSE-H-1 BSE (H type); natural case from Poland NVRI Ca-BSE-H-2 BSE (H type); natural case from France ANSES Ca-BSE-L-1 BSE (L type); natural case from Poland NVRI Ca-BSE-L-2 BSE (L type); natural case from Italy IZSPLV Sh-BSE-3 ARQ/ARQ sheep inoculated with classical BSE ISS 42 Sh-BSE-4 ARQ/ARQ sheep inoculated with classical BSE ISS 42 Sh-BSE-5 ARQ/AHQ sheep inoculated with classical BSE ISS Sh-BSE-6 ARQ/ARH sheep inoculated with classical BSE ISS vCJD-Sp vCJD-infected case Met129Met; Spain BHUFA vCJD-UK vCJD-infected case Met129Met; UK (RU/98/148) CJDRC vCJD-Sp/TgHu-340 Pool of terminally ill human TgHu-340 transgenic mice inoculated with vCJD-Sp CISA 21 sCJD MM1 Type 1 sCJD Met129Met-infected case ISS 8 sCJD MM1/TgHu-340 Pool of terminally ill human TgHu-340 transgenic mice inoculated with sCJD MM1 (after 2 passages in TgHu-340) CISA SS-N799-97 Naturally scrapie-infected sheep, ARQ/ARQ; Spain (799–97) NRL SS-10 Naturally scrapie-infected sheep, ARQ/ARQ; Italy (SS-10) ISS 139A/vole (4th passage) Terminally ill vole inoculated with 139A (3rd passage) ISS 9 SS-3/vole (4th passage) Terminally ill vole inoculated with SS3 ARQ/ARQ from Italian scrapie case (3rd passage) ISS 14 SS-7/vole (3rd passage) Terminally ill vole inoculated with SS-7 (2nd passage) ISS 10 Ca-BSE-1/vole (2nd passage) Terminally ill vole inoculated with Ca-BSE-1 (2nd passage) ISS Ca-BSE-1/vole (4th passage) Terminally ill vole inoculated with Ca-BSE-1 (4th passage) ISS Open in a separate window a ISS, Istituto Superiore di Sanità, Rome, Italy; VLA, Veterinary Laboratory Agency, New Haw, Addlestone, Surrey, UK; NVRI, National Veterinary Research Institute, Pulawy, Poland; ANSES, Agence Française de Sécurité Sanitaire de l'Alimentation, de l'Environnement et du Travail, Lyon, France; IZSPLV, Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Turin, Italy; BHUFA, Biobanco Hospital Universitario Fundación Alcorcón, Alcorcón, Spain; CJDRC, CJD Resource Centre-National Institute for Biological Standards and Control, South Mimms, Potters Bar, UK; CISA, Centro de Investigación en Sanidad Animal, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Valdeolmos, Madrid, Spain; NRL, National Reference Laboratory, Zaragoza, Spain.

Techniques: Transgenic Assay